Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Male-to-Male Sexual Transmission of Zika Virus — Texas, January 2016





D. Trew Deckard, PA-C1; Wendy M. Chung, MD2; John T. Brooks, MD3; Jessica C. Smith, MPH2; Senait Woldai, MPH2; Morgan Hennessey, DVM4,5; Natalie Kwit, DVM4,5; Paul Mead, MD4 (View author affiliations)

View suggested citation


Summary

What is already known about this topic?

Although Zika virus is spread primarily by Aedes species mosquitoes, published case reports have documented sexual transmission from infected men to their female sex partners through vaginal sex.

What is added by this report?

This is the first report of transmission of Zika virus from an infected man to a sex partner through anal sex.

What are the implications for public health practice?

Sexual transmission through both vaginal and anal sex is an emerging mode of Zika virus infection that might contribute to more illness than was anticipated when the outbreak was first recognized. Cases of sexually transmitted Zika virus infection should be reported to public health agencies and can help inform recommendations to prevent Zika virus infections.


Zika virus infection has been linked to increased risk for Guillain-Barré syndrome and adverse fetal outcomes, including congenital microcephaly. In January 2016, after notification from a local health care provider, an investigation by Dallas County Health and Human Services (DCHHS) identified a case of sexual transmission of Zika virus between a man with recent travel to an area of active Zika virus transmission (patient A) and his nontraveling male partner (patient B). At this time, there had been one prior case report of sexual transmission of Zika virus (1). The present case report indicates Zika virus can be transmitted through anal sex, as well as vaginal sex. Identification and investigation of cases of sexual transmission of Zika virus in nonendemic areas present valuable opportunities to inform recommendations to prevent sexual transmission of Zika virus.

Epidemiologic Investigation

In January 2016, 2 days after returning to Dallas, Texas, from a 1-week visit to Venezuela, patient A developed subjective fever, pruritic rash on his upper body and face, and conjunctivitis lasting 3 days. Both 1 day before and 1 day after his symptom onset (Day 0), patient A had condomless insertive anal sex with patient B. Patient A reported that during and after illness he experienced no symptoms of prostatitis or dysuria, and noted no macroscopic hematospermia.

On Day 7, patient B developed a subjective fever, myalgia, headache, lethargy, and malaise; a few days later, he developed a slightly pruritic rash on his torso and arms, small joint arthritis of his hands and feet, and conjunctivitis. All symptoms resolved after 1 week. On Day 11, while still symptomatic, patient B visited his primary care provider for evaluation. Suspecting Zika virus infection, the provider obtained serum specimens from patient B on Day 11 (4 days after patient B’s illness onset), and from both patients A and B on Day 14 (14 and 7 days after respective illness onsets). On Day 24, semen, urine, and saliva specimens were collected from both patients (24 and 17 days after respective illness onsets).

Patient A had traveled regularly to Central and South America for many years. During his recent trip to Venezuela, he reported that multiple persons in the area he visited were experiencing symptoms consistent with Zika virus disease; autochthonous transmission of Zika virus had been confirmed in Venezuela in late November 2015.* Patient B had not recently traveled outside of the United States and had never traveled to countries with active autochthonous Zika transmission. Neither patient had a history of prior known arboviral infection nor had they received yellow fever or Japanese encephalitis vaccinations. The men had been mutually monogamous for more than 10 years and had no major medical illnesses or history of sexually transmitted infections. Neither patient reported ulcerative anal or genital lesions.

Laboratory Investigation

Samples of all clinical specimens were sent by DCHHS to CDC. Patient A’s serum from 14 days after illness onset and patient B’s serum from 4 days after illness onset contained no detectable Zika virus RNA using reverse transcription polymerase chain reaction (RT-PCR) testing (Table) (2). Sera from both patients demonstrated positive immunoglobulin M (IgM) responses by capture ELISA for Zika virus and dengue virus, but not for chikungunya virus (Table) (2). Plaque-reduction neutralization tests (3) indicated that patient A had been infected with Zika virus, dengue virus serotype 1, or both, but that patient B had been infected only with Zika virus. Urine and saliva specimens collected from patients A and B at 24 and 17 days after respective illness onsets had no detectable Zika virus by RT-PCR.

Semen specimens collected at 24 and 17 days from each man were tested for Zika virus by RT-PCR both by CDC and DCHHS using the same two sets of primers (2). At CDC, neither sample had detectable Zika virus with either primer set after 37 cycles. At DCHHS, which pretreated the thawed semen samples with dithiothreitol (used to induce liquefaction of viscous specimens and potentially increase detection of RT-PCR targets), patient B’s specimen was negative. Patient A’s specimen had Zika virus detected at 35 cycles with one primer set but produced no signal after 37 cycles with the other primer set. Patient A’s semen results were thus deemed equivocal.

Environmental Investigation

Although Dallas is within the geographic range of the Zika virus mosquito vectors Aedes aegypti and Ae. albopictus, seasonal winter temperatures in the area during the week of the traveler’s return were not permissive for Aedes activity. Maximum area temperatures during the week of the traveler’s return were <12°C (<54°F) and thus not suitable for overwintering Aedes eggs to hatch and resulting larvae to survive. BG-Sentinel (Biogents AG, Regensberg, Germany) and gravid mosquito traps placed around the residential areas of patients A and B in January yielded only Culex but no Aedes mosquitoes.

Discussion

In addition to the present case report, at least five other cases of sexually transmitted Zika virus infection supported by laboratory evidence have now been reported in the published literature; all were male-to-female transmissions involving vaginal sex. All of the male travelers had symptoms consistent with Zika virus infection and could have transmitted infections to their sex partners a few days before or after as well as during the time symptoms appeared (35). In this case report, patient B’s potential exposures occurred both before and just after initial appearance of symptoms in the traveler, which is the time when blood viremia appears to be highest (i.e., as clinical signs and symptoms of infection emerge).§

Transmission of Zika virus to patient B by Ae. aegypti or albopictus was unlikely based on environmental conditions. Even if these mosquito species had been present and active, the time from exposure to illness in patient B (i.e., 6–8 days) was shorter than the minimum estimated time required for Aedes to become infectious had a mosquito ingested a Zika virus-infected blood meal from patient A (i.e., Ae. aegypti extrinsic incubation period is a minimum estimated duration of 10 days) (6,7), and for patient B once infected to have then developed illness (i.e., 3–12 days).

Studies investigating seminal shedding of infection-competent Zika virus, including its incidence, pattern (e.g., intermittent shedding or a steady decay), and duration are ongoing. At the time of Patient B’s clinical presentation, there had been only one published report describing testing of semen from a man with Zika virus infection (8); studies of semen from two additional men have since been reported (9,10). Zika virus has been detected by RT-PCR and isolated in culture from the semen of two men at least 2 weeks after onset of illnesses (8,10) and possibly up to 10 weeks after illness in one of these cases (8). One report described Zika virus detectable in semen by RT-PCR 62 days after illness onset; culture was not performed (9). In two men, Zika virus was no longer detectable in their blood by RT-PCR when the semen specimens were analyzed (8,9). None of the three men provided follow-up semen specimens to determine when Zika virus was no longer detectable. Notably, all men in the five case reports and the three semen studies, as well as patient A, experienced symptomatic illness. In the report of the sexual transmission case that occurred in 2008 (1) and of the man with culturable Zika virus in semen in 2013 (8), symptoms also included hematospermia.

Identifying and characterizing cases of sexually transmitted Zika virus infection in areas experiencing intense autochthonous vector-borne Zika virus transmission is challenging. Reports of sexual transmission identified in areas where autochthonous transmission is not occurring offer unique and important opportunities to learn about this emerging mode of transmission and rapidly inform and refine interim prevention recommendations. Such cases highlight the need for clinicians to remain vigilant for and continue reporting any suspected cases of Zika virus infection to their state or local health departments, including suspected infections in symptomatic persons without travel history, but who report unprotected sexual contact with a person who has traveled to an area with active Zika virus transmission.

Acknowledgments

Patients A and B; Division of Vector-Borne Disease Arboviral Laboratory, CDC, Ft. Collins, Colorado; Nicole Evert, Texas Department of State Health Services; Scott Sawlis, Spencer Lockwood, Environmental Health Vector Control Division, Dallas County Health and Human Services, Texas; Joey Stringer, Daniel Serinaldi, LRN Laboratory, Dallas County Health and Human Services, Texas.


Corresponding author: John T. Brooks, MD, zud4@cdc.gov, 404-639-3894.

1Medical office of Steven M. Pounders, MD, Dallas, Texas; 2Acute Communicable Disease Epidemiology Division, Dallas County Health and Human Services, Texas; 3Division of HIV/AIDS Prevention, National Center for HIV, Hepatitis, TB and STD Prevention, CDC; 4Division of Vector-Borne Diseases, National Center for Emerging and Zoonotic Infectious Diseases, CDC, Ft. Collins, Colorado; 5Epidemic Intelligence Service, CDC.

References

  1. Foy BD, Kobylinski KC, Chilson Foy JL, et al. Probable non-vector-borne transmission of Zika virus, Colorado, USA. Emerg Infect Dis 2011;17:880–2. CrossRef PubMed
  2. Lanciotti RS, Kosoy OL, Laven JJ, et al. Genetic and serologic properties of Zika virus associated with an epidemic, Yap State, Micronesia, 2007. Emerg Infect Dis 2008;14:1232–9. CrossRef PubMed
  3. Calisher CH, Karabatsos N, Dalrymple JM, et al. Antigenic relationships between flaviviruses as determined by cross-neutralization tests with polyclonal antisera. J Gen Virol 1989;70:37–43. CrossRef PubMed
  4. Venturi G, Zammarchi L, Fortuna C, et al. An autochthonous case of Zika due to possible sexual transmission, Florence, Italy, 2014. Euro Surveill 2016;21:30148. CrossRef PubMed
  5. Hills SL, Russell K, Hennessey M, et al. Transmission of Zika virus through sexual contact with travelers to areas of ongoing transmission—continental United States, 2016. MMWR Morb Mortal Wkly Rep 2016;65:215–6. CrossRef PubMed
  6. Boorman JP, Porterfield JS. A simple technique for infection of mosquitoes with viruses; transmission of Zika virus. Trans R Soc Trop Med Hyg 1956;50:238–42. CrossRef PubMed
  7. Hayes EB. Zika virus outside Africa. Emerg Infect Dis 2009;15:1347–50. CrossRef PubMed
  8. Musso D, Roche C, Robin E, Nhan T, Teissier A, Cao-Lormeau VM. Potential sexual transmission of Zika virus. Emerg Infect Dis 2015;21:359–61. CrossRef PubMed
  9. Atkinson B, Hearn P, Afrough B, et al. Detection of Zika virus in semen. Emerg Infect Dis 2016;22. CrossRef
  10. Mansuy JM, Dutertre M, Mengelle C, et al. Zika virus: high infectious viral load in semen, a new sexually transmitted pathogen? Lancet Infect Dis 2016;16:405. CrossRef PubMed

* Pan American Health Organization and World Health Organization Regional Office of the Americas. Epidemiological alert. Neurological syndrome, congenital malformations, and Zika virus infection. Implications for public health in the Americas — 1 December 2015.

National Weather Service Climate Prediction Center. Temperature data for Dallas-Ft. Worth, Texas. 2016. http://www.cpc.ncep.noaa.gov/products/tanal/temp_analyses.php.

§http://www.who.int/bulletin/online_first/16-171207.pdf.

Return to your place in the textTABLE. Reverse transcription polymerase chain reaction (RT-PCR) and serologic testing of serum from patients A and B — Texas, January 2016
Patient Days after symptom onset ZIKV RT-PCR ZIKV IgM* DENV IgM CHIK IgM ZIKV PRNT DENV-1 PRNT DENV-2 PRNT
Patient A 14 Negative Positive Positive Negative >20,480 >20,480 5,120
Patient B 4 Negative ND ND ND 160 <10 <10
Patient B 7 Negative Positive Positive Negative 2,560 10 <10

Abbreviations: CHIKV = chikungunya virus; DENV-1 or 2 = dengue virus serotype type 1 or 2; IgM = immunoglobulin M; ND = not done; PRNT = plaque-reduction neutralization test; ZIKV = Zika virus.
* IgM antibody capture-enzyme linked immunosorbent assay.
Serum dilution-plaque reduction neutralization test, titers of neutralizing antibodies to ZIKV, DENV-1, and DENV-2.

Suggested citation for this article: Deckard DT, Chung WM, Brooks JT, et al. Male-to-Male Sexual Transmission of Zika Virus — Texas, January 2016. MMWR Morb Mortal Wkly Rep 2016;65:372–374. DOI: http://dx.doi.org/10.15585/mmwr.mm6514a3.

Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.
References to non-CDC sites on the Internet are provided as a service to MMWR readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of pages found at these sites. URL addresses listed in MMWR were current as of the date of publication.

All HTML versions of MMWR articles are generated from final proofs through an automated process. This conversion might result in character translation or format errors in the HTML version. Users are referred to the electronic PDF version (https://www.cdc.gov/mmwr) and/or the original MMWR paper copy for printable versions of official text, figures, and tables.

Questions or messages regarding errors in formatting should be addressed to mmwrq@cdc.gov.

TOP